1 October - 31 December 2023
- Net sales reached SEK 6,4 (5,6) million, an increase of 16,1 percent
- Operating loss amounted to SEK -3,4 (-3,1) million
- The operating result includes one-time costs of approximately SEK 2 million related to organizational changes
- Loss after taxes SEK -3,4 (-3,1) million
- Earnings per share, SEK (basic and diluted) amounted to SEK -0,04 (-0,05)
- Cash flow from operating activities amounted to SEK -5,6 (-3,2) million
Significant events during period
- Extraordinary general meeting on October 12th - New election of Per Langö, Tomas Eriksson, Paul de Potocki and Tom Rönnlund as regular board members and re-election of Marianne Östlund and Annette Colin as regular board members
- Per Langö elected as chairman of the board on October on 12th
- Anders Kristensson appointed as new CEO on October 27th
- New election committee appointed on November 29th
- Niclas Nyström appointed new CFO on December 6th
- Agreement with Esbjerg Sygehus in Denmark
1 January-31 December
- Net sales reached SEK 22,2 (17,4), an increase of 27,5 percent
- Operating loss amounted to SEK -16,9 (-10,9) million
- The operating result includes one-time costs of approximately SEK 4 million related to organizational changes
- Loss after taxes amounted to SEK -17,0 (-11,1) million
- Earnings per share, SEK (basic and diluted) amounted to SEK -0,25 (-0,21)
- Cash flow from operating activities amounted to SEK -23,8 (-16,2) million
- Cash and cash equivalents amounted to SEK 15,4 (12,3) million per December 31st 2023
Significant events after the end of the period
- New management team appointed on February 15th
| Key figures | ||||
| (SEK Million) | oct-dec 2023 | oct-dec 2022 | jan-dec 2023 | jan-dec 2022 |
| Net sales | 6,4 | 5,6 | 22,2 | 17,4 |
| Gross Margin, % | 73,4 | 70,3 | 70,5 | 73,9 |
| Operating profit/loss, EBIT | -3,4 | -3,1 | -16,9 | -10,9 |
| Cashflow from operating activities | -5,6 | -3,2 | -23,8 | -16,2 |
| Cash and cash equivalents | 15,4 | 12,3 | 15,4 | 12,3 |
| Average number of employees | 7,0 | 7,5 | 8,5 | 8,0 |
For further information, please contact:
Anders Kristensson, CEO
Tel. +46 (0) 769 42 12 16
Email: anders.kristensson@prostalund.com
About ProstaLund
ProstaLund AB is a Swedish medical technology company and a leading developer and manufacturer of innovative urological devices and treatments. The company's lead product, CoreTherm, is a patented Thermotherapy treatment method for Benign Prostatic Hyperplasia (BPH) which can be tailored to suit the needs of each individual patient. CoreTherm is used today in hospitals and clinics in Sweden and worldwide. ProstaLund is listed on the Nasdaq First North Growth Market.
Certified Adviser:
Västra Hamnen Corporate Finance AB
Phone: +46 40 200 250
E-mail: ca@vhcorp.se
This information is information that ProstaLund AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2024-02-16 08:15 CET.
